Galantamine Therapy in Alzheimer's Disease

Introduction to Galantamine

Galantamine is a treatment option for Alzheimer's disease, with the American Academy of Family Physicians recommending its use for patients with mild to moderate Alzheimer's disease, starting with a dose of 4 mg twice daily, gradually increased to 8-12 mg twice daily to improve cognitive function, global assessment, and activities of daily living 1

The recommended dosing regimen for galantamine is to start with 4 mg twice daily, increasing to 8 mg twice daily (16 mg/day) after 4 weeks, and considering an increase to 12 mg twice daily (24 mg/day) based on individual response, with a maximum dose of 16 mg/day for moderate hepatic impairment and contraindication in severe hepatic impairment 1
Taking galantamine with meals can reduce gastrointestinal side effects, and dose escalation should be done gradually, as gastrointestinal effects are most pronounced during this phase 1
Treatment discontinuation rates range from 8% to 54% with galantamine versus 4% to 17% with placebo, with higher doses associated with higher discontinuation rates 2

Galantamine increases the likelihood of improvement or stabilization on the CIBIC-plus scale, with a relative risk of 1.22, and significantly improves functional ability as measured by the Disability Assessment for Dementia scale 2
Memantine shows statistically significant improvement in cognition scores and global assessment with the CIBIC-plus for patients with moderate to severe Alzheimer's disease, with limited evidence of improvement in quality of life, caregiver burden, and resource utilization 3
One large trial comparing donepezil with rivastigmine showed statistical differences in global function and activities of daily living, favoring rivastigmine 3
Increasing the galantamine dose to 16-24 mg daily or adding memantine to the current regimen may provide additional benefit for patients experiencing moderate deterioration despite treatment with galantamine 12 mg daily 1, 3

Galantamine commonly causes gastrointestinal side effects including nausea, vomiting, diarrhea, and decreased appetite, with anorexia having the highest relative risk (3.41 times higher than placebo) 2
Women and patients with lower body weight are more likely to experience nausea and vomiting 2
Common side effects of galantamine include gastrointestinal symptoms such as nausea, vomiting, and diarrhea, as well as neurological symptoms like dizziness and headache, which are typically mild to moderate in intensity and usually transient 1, 2

Regular monitoring is recommended for patients on galantamine therapy, particularly for those with renal or hepatic impairment, cardiac conduction abnormalities, or a history of ulcer disease, to minimize potential side effects and optimize the benefit-risk profile 1
Response to galantamine treatment should be evaluated after 6-12 months using physician's global assessment, primary caregiver's report, neuropsychological assessment or mental status questionnaire, and evidence of behavioral or functional changes, with discontinuation criteria including side effects that do not resolve, poor medication adherence, and deterioration that continues at the pre-treatment rate after 6-12 months of treatment 1
Patients who don't respond to one cholinesterase inhibitor may respond to another 1, 2

Most studies of galantamine were 24-26 weeks, and long-term outcomes beyond one year are less well established, with discontinuation rates higher with galantamine than placebo, primarily due to gastrointestinal side effects 2